| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Varicose Ulcer | 24 | 2021 | 55 | 5.500 |
Why?
|
| Varicose Veins | 22 | 2020 | 155 | 5.350 |
Why?
|
| Venous Insufficiency | 20 | 2024 | 108 | 5.250 |
Why?
|
| Glycosaminoglycans | 7 | 2024 | 607 | 2.470 |
Why?
|
| Vena Cava, Inferior | 10 | 2020 | 458 | 2.260 |
Why?
|
| Vasodilation | 9 | 2019 | 962 | 1.820 |
Why?
|
| Vasoconstriction | 10 | 2020 | 592 | 1.800 |
Why?
|
| Aortic Aneurysm, Abdominal | 13 | 2022 | 1228 | 1.280 |
Why?
|
| E-Selectin | 2 | 2022 | 576 | 1.250 |
Why?
|
| Saphenous Vein | 5 | 2024 | 516 | 1.240 |
Why?
|
| Vasoconstrictor Agents | 10 | 2020 | 654 | 1.150 |
Why?
|
| Femoral Artery | 6 | 2016 | 826 | 1.140 |
Why?
|
| Venous Thrombosis | 6 | 2022 | 1303 | 1.130 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2020 | 459 | 1.130 |
Why?
|
| Wound Healing | 11 | 2017 | 2805 | 1.100 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2024 | 632 | 1.080 |
Why?
|
| Matrix Metalloproteinases | 7 | 2017 | 393 | 1.080 |
Why?
|
| Leg | 5 | 2021 | 1088 | 1.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 10 | 2022 | 1428 | 1.000 |
Why?
|
| Veins | 5 | 2017 | 768 | 0.990 |
Why?
|
| Leg Ulcer | 2 | 2016 | 71 | 0.990 |
Why?
|
| Iliac Vein | 3 | 2023 | 70 | 0.860 |
Why?
|
| Muscle, Smooth, Vascular | 8 | 2016 | 1492 | 0.860 |
Why?
|
| Fibroblasts | 10 | 2009 | 4142 | 0.800 |
Why?
|
| Vascular Diseases | 5 | 2023 | 1161 | 0.800 |
Why?
|
| Arterial Occlusive Diseases | 5 | 2016 | 748 | 0.790 |
Why?
|
| Lower Extremity | 8 | 2023 | 1202 | 0.750 |
Why?
|
| Aneurysm | 2 | 2017 | 337 | 0.740 |
Why?
|
| Endothelium, Vascular | 5 | 2019 | 4431 | 0.720 |
Why?
|
| Vascular Surgical Procedures | 10 | 2022 | 1489 | 0.690 |
Why?
|
| Chronic Disease | 23 | 2024 | 9319 | 0.650 |
Why?
|
| Nitric Oxide | 5 | 2019 | 2136 | 0.650 |
Why?
|
| Stockings, Compression | 4 | 2020 | 36 | 0.630 |
Why?
|
| Leukocytes | 4 | 2017 | 2026 | 0.600 |
Why?
|
| Endovascular Procedures | 8 | 2024 | 2183 | 0.590 |
Why?
|
| Endarterectomy, Carotid | 2 | 2022 | 555 | 0.580 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2010 | 488 | 0.550 |
Why?
|
| Thrombophlebitis | 3 | 2014 | 289 | 0.540 |
Why?
|
| Phenylephrine | 8 | 2016 | 293 | 0.520 |
Why?
|
| Intermittent Claudication | 4 | 2016 | 304 | 0.500 |
Why?
|
| Glycocalyx | 1 | 2016 | 97 | 0.480 |
Why?
|
| Portal Vein | 1 | 2017 | 431 | 0.480 |
Why?
|
| Carotid Stenosis | 1 | 2022 | 860 | 0.470 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2013 | 198 | 0.460 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2014 | 1809 | 0.460 |
Why?
|
| Iliac Artery | 3 | 2016 | 343 | 0.440 |
Why?
|
| Colony-Stimulating Factors | 1 | 2014 | 218 | 0.440 |
Why?
|
| Anticoagulants | 3 | 2020 | 4812 | 0.440 |
Why?
|
| Potassium Chloride | 6 | 2011 | 230 | 0.430 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2016 | 97 | 0.420 |
Why?
|
| Drug-Eluting Stents | 1 | 2018 | 681 | 0.400 |
Why?
|
| Calcium Signaling | 3 | 2011 | 733 | 0.390 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 36 | 0.390 |
Why?
|
| Aneurysm, Infected | 1 | 2012 | 82 | 0.390 |
Why?
|
| Venous Pressure | 2 | 2008 | 56 | 0.390 |
Why?
|
| Escin | 1 | 2011 | 2 | 0.390 |
Why?
|
| Cardiovascular Agents | 3 | 2014 | 840 | 0.390 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2011 | 17 | 0.380 |
Why?
|
| Aneurysm, Ruptured | 1 | 2016 | 464 | 0.380 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 8181 | 0.380 |
Why?
|
| Vasodilator Agents | 5 | 2011 | 973 | 0.370 |
Why?
|
| Endarterectomy | 1 | 2011 | 196 | 0.370 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 1027 | 0.360 |
Why?
|
| Biological Factors | 1 | 2011 | 157 | 0.360 |
Why?
|
| Microcirculation | 2 | 2015 | 1272 | 0.360 |
Why?
|
| Aortic Diseases | 4 | 2016 | 735 | 0.350 |
Why?
|
| Axillary Artery | 2 | 2016 | 47 | 0.340 |
Why?
|
| Aneurysm, False | 2 | 2011 | 255 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 10766 | 0.330 |
Why?
|
| Vascular Neoplasms | 1 | 2011 | 166 | 0.330 |
Why?
|
| Angioplasty | 1 | 2011 | 355 | 0.320 |
Why?
|
| Skin | 4 | 2013 | 4484 | 0.320 |
Why?
|
| Tunica Intima | 1 | 2011 | 459 | 0.310 |
Why?
|
| Seat Belts | 1 | 2008 | 60 | 0.300 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 151 | 0.300 |
Why?
|
| Muscle Contraction | 3 | 2020 | 1201 | 0.290 |
Why?
|
| Femoral Vein | 2 | 2020 | 153 | 0.290 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 445 | 0.290 |
Why?
|
| Cytokines | 5 | 2016 | 7396 | 0.280 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2022 | 951 | 0.280 |
Why?
|
| Humans | 86 | 2024 | 761596 | 0.280 |
Why?
|
| Angiotensin II | 4 | 2011 | 849 | 0.280 |
Why?
|
| Treatment Outcome | 25 | 2024 | 64685 | 0.270 |
Why?
|
| Quadriplegia | 1 | 2008 | 226 | 0.270 |
Why?
|
| Laser Therapy | 1 | 2013 | 1092 | 0.270 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 698 | 0.260 |
Why?
|
| Collagenases | 2 | 2016 | 222 | 0.250 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2006 | 618 | 0.250 |
Why?
|
| Metabolome | 1 | 2012 | 989 | 0.250 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 687 | 0.240 |
Why?
|
| Male | 56 | 2024 | 360846 | 0.240 |
Why?
|
| Osteosarcoma | 1 | 2011 | 897 | 0.240 |
Why?
|
| Metabolomics | 1 | 2014 | 1659 | 0.240 |
Why?
|
| Signal Transduction | 7 | 2019 | 23447 | 0.230 |
Why?
|
| Potassium Channels | 1 | 2007 | 537 | 0.230 |
Why?
|
| Aorta, Abdominal | 2 | 2004 | 625 | 0.230 |
Why?
|
| Vertebral Artery Dissection | 1 | 2004 | 51 | 0.230 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 877 | 0.220 |
Why?
|
| Risk Factors | 22 | 2024 | 74213 | 0.220 |
Why?
|
| Rats | 8 | 2019 | 23741 | 0.220 |
Why?
|
| Membrane Potentials | 3 | 2011 | 1090 | 0.220 |
Why?
|
| Cell Proliferation | 4 | 2009 | 10451 | 0.220 |
Why?
|
| Inflammation | 3 | 2016 | 10774 | 0.220 |
Why?
|
| Terminology as Topic | 1 | 2010 | 1530 | 0.220 |
Why?
|
| U937 Cells | 2 | 2014 | 261 | 0.220 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 1407 | 0.210 |
Why?
|
| Abdominal Abscess | 1 | 2004 | 153 | 0.210 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3549 | 0.210 |
Why?
|
| Hernia | 1 | 2003 | 68 | 0.210 |
Why?
|
| Cross Infection | 1 | 2012 | 1422 | 0.210 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2016 | 231 | 0.210 |
Why?
|
| Nitric Oxide Synthase | 3 | 2011 | 908 | 0.200 |
Why?
|
| Hospital Costs | 1 | 2008 | 947 | 0.200 |
Why?
|
| Cell Division | 5 | 2004 | 4465 | 0.200 |
Why?
|
| Anesthesia, Local | 1 | 2024 | 277 | 0.200 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3769 | 0.200 |
Why?
|
| Lymphedema | 2 | 2022 | 525 | 0.200 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2571 | 0.200 |
Why?
|
| Constriction, Pathologic | 2 | 2018 | 1096 | 0.200 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 212 | 0.200 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 2209 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 691 | 0.190 |
Why?
|
| Sclerotherapy | 2 | 2014 | 182 | 0.190 |
Why?
|
| Blood Vessels | 1 | 2007 | 1113 | 0.190 |
Why?
|
| Lipids | 1 | 2012 | 3341 | 0.190 |
Why?
|
| Anesthesia, Conduction | 1 | 2024 | 262 | 0.190 |
Why?
|
| Baroreflex | 1 | 2022 | 149 | 0.180 |
Why?
|
| Laparotomy | 1 | 2003 | 457 | 0.180 |
Why?
|
| Proteomics | 1 | 2014 | 3848 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 8527 | 0.180 |
Why?
|
| Animals | 21 | 2020 | 168475 | 0.180 |
Why?
|
| Cyclic GMP | 2 | 2011 | 395 | 0.180 |
Why?
|
| Fluid Shifts | 1 | 2020 | 20 | 0.180 |
Why?
|
| Receptors, Adrenergic, alpha | 2 | 2010 | 146 | 0.170 |
Why?
|
| Popliteal Artery | 1 | 2002 | 310 | 0.170 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2011 | 153 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2020 | 2919 | 0.170 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2008 | 592 | 0.170 |
Why?
|
| Sarcoma | 1 | 2011 | 1801 | 0.170 |
Why?
|
| Hernia, Ventral | 1 | 2003 | 218 | 0.170 |
Why?
|
| Flavonoids | 2 | 2017 | 445 | 0.160 |
Why?
|
| P-Selectin | 1 | 2022 | 597 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 1 | 2004 | 487 | 0.160 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 526 | 0.160 |
Why?
|
| Potassium Channel Blockers | 2 | 2011 | 161 | 0.160 |
Why?
|
| Peripheral Arterial Disease | 2 | 2023 | 1273 | 0.160 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1055 | 0.160 |
Why?
|
| Cardiology | 3 | 2022 | 1656 | 0.160 |
Why?
|
| Ischemia | 2 | 2019 | 1884 | 0.160 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2002 | 292 | 0.160 |
Why?
|
| Macrophages | 1 | 2014 | 5767 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 1486 | 0.160 |
Why?
|
| Extracellular Fluid | 1 | 2020 | 165 | 0.160 |
Why?
|
| Genomics | 1 | 2014 | 5821 | 0.150 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2010 | 260 | 0.150 |
Why?
|
| Inflammation Mediators | 3 | 2024 | 1886 | 0.150 |
Why?
|
| Middle Aged | 31 | 2024 | 220921 | 0.150 |
Why?
|
| Aged | 29 | 2024 | 169310 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2011 | 361 | 0.150 |
Why?
|
| Carotid Arteries | 1 | 2022 | 941 | 0.150 |
Why?
|
| Compression Bandages | 2 | 2014 | 14 | 0.140 |
Why?
|
| Postthrombotic Syndrome | 2 | 2014 | 28 | 0.140 |
Why?
|
| Anesthesia, General | 1 | 2024 | 1174 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2012 | 1835 | 0.140 |
Why?
|
| Aortography | 2 | 2012 | 421 | 0.140 |
Why?
|
| Organ Culture Techniques | 1 | 2019 | 795 | 0.140 |
Why?
|
| Cell Movement | 2 | 2016 | 5205 | 0.140 |
Why?
|
| Female | 38 | 2024 | 392705 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 2001 | 1170 | 0.130 |
Why?
|
| Hemodynamics | 3 | 2017 | 4160 | 0.130 |
Why?
|
| Time Factors | 13 | 2024 | 39969 | 0.130 |
Why?
|
| Cells, Cultured | 9 | 2024 | 18966 | 0.130 |
Why?
|
| Ligation | 1 | 2016 | 448 | 0.130 |
Why?
|
| Stents | 4 | 2023 | 3179 | 0.130 |
Why?
|
| Dilatation, Pathologic | 2 | 2008 | 527 | 0.130 |
Why?
|
| Walking | 2 | 2020 | 1198 | 0.120 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 3713 | 0.120 |
Why?
|
| Thrombolytic Therapy | 2 | 2015 | 2064 | 0.120 |
Why?
|
| Postoperative Complications | 7 | 2024 | 15633 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 462 | 0.120 |
Why?
|
| Veterans Health | 1 | 2016 | 215 | 0.120 |
Why?
|
| Actins | 1 | 2001 | 2050 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11530 | 0.110 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 15266 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2019 | 825 | 0.110 |
Why?
|
| Spine | 1 | 2020 | 1118 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 11076 | 0.100 |
Why?
|
| Prostaglandins I | 1 | 2011 | 13 | 0.100 |
Why?
|
| Probability | 3 | 2010 | 2477 | 0.100 |
Why?
|
| Diosmin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2011 | 18 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 4176 | 0.100 |
Why?
|
| Patient Preference | 1 | 2019 | 927 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2004 | 2017 | 0.100 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 3415 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2012 | 20568 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 110 | 0.090 |
Why?
|
| Isometric Contraction | 2 | 2008 | 150 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 629 | 0.090 |
Why?
|
| Pressoreceptors | 1 | 2010 | 99 | 0.090 |
Why?
|
| Risk Assessment | 11 | 2024 | 23996 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 1380 | 0.090 |
Why?
|
| Observer Variation | 1 | 2017 | 2606 | 0.090 |
Why?
|
| Body Composition | 1 | 2020 | 2426 | 0.090 |
Why?
|
| Evidence-Based Medicine | 4 | 2015 | 3688 | 0.090 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 891 | 0.090 |
Why?
|
| Prognosis | 5 | 2019 | 29629 | 0.090 |
Why?
|
| Prospective Studies | 9 | 2020 | 54423 | 0.090 |
Why?
|
| Apoptosis | 2 | 2008 | 9490 | 0.090 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 141 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1964 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 150 | 0.080 |
Why?
|
| Logistic Models | 5 | 2023 | 13255 | 0.080 |
Why?
|
| Chemokines | 1 | 2014 | 959 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 17904 | 0.080 |
Why?
|
| Resistin | 1 | 2010 | 172 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 168 | 0.080 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2011 | 293 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1998 | 0.080 |
Why?
|
| Thrombectomy | 2 | 2012 | 705 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2011 | 705 | 0.080 |
Why?
|
| Autopsy | 1 | 2012 | 1009 | 0.080 |
Why?
|
| Vascular Patency | 1 | 2011 | 911 | 0.080 |
Why?
|
| Prosthesis Design | 2 | 2022 | 2115 | 0.080 |
Why?
|
| Nitriles | 2 | 2010 | 971 | 0.080 |
Why?
|
| Wheelchairs | 1 | 2008 | 78 | 0.070 |
Why?
|
| Acetylcholine | 1 | 2010 | 629 | 0.070 |
Why?
|
| Adult | 17 | 2024 | 221210 | 0.070 |
Why?
|
| Reference Values | 2 | 2008 | 4920 | 0.070 |
Why?
|
| Scleroderma, Localized | 1 | 2008 | 87 | 0.070 |
Why?
|
| Poisson Distribution | 1 | 2008 | 504 | 0.070 |
Why?
|
| Cromakalim | 1 | 2007 | 22 | 0.070 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2007 | 43 | 0.070 |
Why?
|
| Odds Ratio | 5 | 2022 | 9647 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2007 | 21 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 290 | 0.070 |
Why?
|
| Polytetrafluoroethylene | 1 | 2008 | 245 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 619 | 0.070 |
Why?
|
| Hospital Charges | 1 | 2008 | 350 | 0.070 |
Why?
|
| Biopsy | 2 | 2011 | 6766 | 0.070 |
Why?
|
| Indomethacin | 1 | 2007 | 325 | 0.070 |
Why?
|
| Hyperemia | 1 | 2007 | 221 | 0.070 |
Why?
|
| Phenols | 1 | 2010 | 517 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2008 | 256 | 0.070 |
Why?
|
| Acute Disease | 3 | 2012 | 7237 | 0.070 |
Why?
|
| Retrospective Studies | 10 | 2024 | 80647 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 2206 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22176 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3810 | 0.060 |
Why?
|
| Epoprostenol | 1 | 2007 | 247 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 583 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 366 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 1651 | 0.060 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2010 | 529 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 1784 | 0.060 |
Why?
|
| Exudates and Transudates | 1 | 2006 | 174 | 0.060 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 2004 | 8 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 360 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2010 | 697 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 629 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2008 | 1646 | 0.060 |
Why?
|
| Leukemia | 1 | 2013 | 1522 | 0.060 |
Why?
|
| Pressure | 1 | 2008 | 1154 | 0.060 |
Why?
|
| Collagen | 1 | 2013 | 2638 | 0.060 |
Why?
|
| Rifabutin | 1 | 2004 | 59 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 754 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1136 | 0.060 |
Why?
|
| Thigh | 1 | 2006 | 241 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 4016 | 0.060 |
Why?
|
| Coronary Restenosis | 1 | 2007 | 396 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2008 | 1248 | 0.060 |
Why?
|
| Age Factors | 3 | 2017 | 18399 | 0.060 |
Why?
|
| Sodium, Dietary | 1 | 2008 | 425 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2006 | 332 | 0.060 |
Why?
|
| Adiponectin | 1 | 2010 | 1113 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1432 | 0.060 |
Why?
|
| Popliteal Vein | 1 | 2023 | 43 | 0.060 |
Why?
|
| Random Allocation | 1 | 2008 | 2395 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 1265 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 58984 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2004 | 326 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2011 | 15843 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 1301 | 0.050 |
Why?
|
| Aortic Aneurysm | 1 | 2008 | 648 | 0.050 |
Why?
|
| Estrogens | 1 | 2010 | 1522 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 615 | 0.050 |
Why?
|
| Takayasu Arteritis | 1 | 2004 | 105 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2008 | 1187 | 0.050 |
Why?
|
| Jugular Veins | 1 | 2004 | 210 | 0.050 |
Why?
|
| Isoniazid | 1 | 2004 | 283 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2010 | 4125 | 0.050 |
Why?
|
| Vascular Fistula | 1 | 2003 | 50 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2014 | 3905 | 0.050 |
Why?
|
| Estradiol | 1 | 2010 | 1937 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 10212 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2008 | 1204 | 0.050 |
Why?
|
| Duodenal Diseases | 1 | 2003 | 100 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 672 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 1252 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 2084 | 0.050 |
Why?
|
| Tibial Arteries | 1 | 2002 | 60 | 0.050 |
Why?
|
| Polyethylene Terephthalates | 1 | 2002 | 113 | 0.050 |
Why?
|
| Imidazoles | 1 | 2008 | 1180 | 0.050 |
Why?
|
| Intestinal Fistula | 1 | 2003 | 142 | 0.050 |
Why?
|
| Hypertension | 3 | 2017 | 8540 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 14665 | 0.050 |
Why?
|
| Debridement | 1 | 2004 | 493 | 0.050 |
Why?
|
| Endoleak | 1 | 2022 | 111 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 2567 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 1726 | 0.050 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 1496 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 5672 | 0.040 |
Why?
|
| Radiography | 1 | 2011 | 6965 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2015 | 3802 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 673 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 13510 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 3530 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 1349 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2008 | 8321 | 0.040 |
Why?
|
| Length of Stay | 2 | 2016 | 6426 | 0.040 |
Why?
|
| Patient Selection | 3 | 2022 | 4244 | 0.040 |
Why?
|
| Fibronectins | 2 | 2003 | 723 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2013 | 3242 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2010 | 2009 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2022 | 364 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2001 | 563 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2021 | 704 | 0.040 |
Why?
|
| Device Removal | 1 | 2004 | 630 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12973 | 0.040 |
Why?
|
| Drainage | 1 | 2004 | 1157 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 1999 | 369 | 0.040 |
Why?
|
| Linear Models | 1 | 2008 | 5872 | 0.040 |
Why?
|
| Propensity Score | 2 | 2016 | 1913 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2011 | 5035 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 1999 | 574 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2011 | 8481 | 0.040 |
Why?
|
| Physicians | 1 | 2016 | 4591 | 0.040 |
Why?
|
| Information Seeking Behavior | 1 | 2019 | 116 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 846 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2005 | 868 | 0.040 |
Why?
|
| Bioprosthesis | 1 | 2002 | 591 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2007 | 1231 | 0.040 |
Why?
|
| Pericardium | 1 | 2002 | 675 | 0.040 |
Why?
|
| Streptonigrin | 1 | 1997 | 1 | 0.040 |
Why?
|
| Prevalence | 1 | 2014 | 15733 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 1999 | 219 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4352 | 0.030 |
Why?
|
| Blood Loss, Surgical | 2 | 2016 | 638 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12059 | 0.030 |
Why?
|
| Pyridines | 1 | 2008 | 2875 | 0.030 |
Why?
|
| Sex Factors | 1 | 2010 | 10554 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1626 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2004 | 1375 | 0.030 |
Why?
|
| Cell Death | 1 | 2001 | 1679 | 0.030 |
Why?
|
| Palliative Care | 1 | 2011 | 3598 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2020 | 757 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2850 | 0.030 |
Why?
|
| Permeability | 1 | 2017 | 723 | 0.030 |
Why?
|
| United States | 6 | 2022 | 72340 | 0.030 |
Why?
|
| Peptides | 1 | 2007 | 4358 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2024 | 3208 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 1702 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 39106 | 0.030 |
Why?
|
| Capillaries | 1 | 2017 | 755 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7406 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2004 | 1914 | 0.030 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2014 | 148 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 678 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 2472 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 59260 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 766 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2079 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 1699 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 18255 | 0.030 |
Why?
|
| Pneumonia | 1 | 2004 | 2143 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3124 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4576 | 0.020 |
Why?
|
| Echinomycin | 1 | 2010 | 2 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 928 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2007 | 3407 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1674 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1999 | 2932 | 0.020 |
Why?
|
| Butadienes | 1 | 2010 | 107 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1999 | 6228 | 0.020 |
Why?
|
| Guanylate Cyclase | 1 | 2011 | 205 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2016 | 7968 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2010 | 198 | 0.020 |
Why?
|
| Renin | 1 | 2011 | 641 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 3204 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2010 | 318 | 0.020 |
Why?
|
| Thrombosis | 1 | 2003 | 2942 | 0.020 |
Why?
|
| Smoking | 1 | 2005 | 9053 | 0.020 |
Why?
|
| Histone Demethylases | 1 | 2011 | 323 | 0.020 |
Why?
|
| Adipokines | 1 | 2010 | 310 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3725 | 0.020 |
Why?
|
| Muscle Relaxation | 1 | 2008 | 138 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2010 | 2186 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2015 | 2495 | 0.020 |
Why?
|
| Algorithms | 2 | 2005 | 14033 | 0.020 |
Why?
|
| Aldosterone | 1 | 2011 | 870 | 0.020 |
Why?
|
| Cyclin D | 1 | 2006 | 72 | 0.020 |
Why?
|
| Reoperation | 1 | 2016 | 4303 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 13381 | 0.020 |
Why?
|
| Pregnancy | 1 | 2007 | 29890 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2011 | 1096 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 2115 | 0.020 |
Why?
|
| Angiography | 1 | 2010 | 1595 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2019 | 5079 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2011 | 14417 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2010 | 2927 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2010 | 12794 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 12463 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 8710 | 0.010 |
Why?
|
| Cyclins | 1 | 2006 | 594 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 1371 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15601 | 0.010 |
Why?
|
| Hematemesis | 1 | 2003 | 22 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2016 | 3443 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5293 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 15502 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10508 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2001 | 26202 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 2002 | 311 | 0.010 |
Why?
|
| Graft Survival | 1 | 2010 | 3820 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2002 | 983 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 26129 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 8466 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1997 | 162 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4618 | 0.010 |
Why?
|
| Methanol | 1 | 1997 | 92 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 12990 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6484 | 0.010 |
Why?
|
| Drug Stability | 1 | 1997 | 291 | 0.010 |
Why?
|
| Solutions | 1 | 1997 | 412 | 0.010 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2003 | 696 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1997 | 251 | 0.010 |
Why?
|
| Solvents | 1 | 1997 | 295 | 0.010 |
Why?
|
| Quality of Life | 1 | 2017 | 13367 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2007 | 5971 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 14608 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 16592 | 0.010 |
Why?
|
| Mice | 2 | 2011 | 81539 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 2496 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 3076 | 0.010 |
Why?
|
| Temperature | 1 | 1997 | 2226 | 0.010 |
Why?
|
| Diet | 1 | 2008 | 8075 | 0.010 |
Why?
|
| Indoles | 1 | 1997 | 1833 | 0.000 |
Why?
|
| Incidence | 1 | 1999 | 21355 | 0.000 |
Why?
|